Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4111-4120 Newer>

The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
The Motley Fool September 7, 2007 Billy Fisher	Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively.
The Motley Fool September 7, 2007 Brian Orelli	Clinical Data Gets Personal Clinical Data's lead compound Vilazodone posts strong phase 3 results. The company is searching for common genetic markers among patients who responded positively to the drug.
The Motley Fool September 6, 2007 Ryan Fuhrmann	Bio-Reference Labs Passes the Test Small-cap lab-testing firm Bio-Reference Labs third-quarter results beat analysts projections by a decent margin, again proving it can compete with the big boys in the highly competitive New York metro area.
The Motley Fool September 6, 2007 Brian Lawler	NeurogesX Feels No Pain Investors reward the drugmaker for positive study results.
The Motley Fool September 6, 2007 Markos Kaminis	The Roller Coaster That Is Martek Martek BioSciences, producer of DHA fatty acid, continues its up-and-down pattern. Most recently, the stock prices collapsed after Q3 reports when the company found itself carrying excess capacity. Long-term investors, this may be a good time to buy.
The Motley Fool September 6, 2007 Brian Lawler	Amgen's Congressional Helpers Lawmakers push to ease restrictions on anemia compounds from Amgen and Johnson & Johnson. Investors, take note.
The Motley Fool September 6, 2007 Rick Aristotle Munarriz	Britain Unleashes the Wolfman The chimerical future is here. Britain's Human Fertilization and Embryo Authority announced that it will permit scientists to create human-animal hybrid embryos.
The Motley Fool September 6, 2007 Brian Lawler	Encysive, Please Stop Its failure to acquiesce to the FDA's request means the competition is going forward as this drugmaker's product stays stagnant. Investors, take note.
The Motley Fool September 6, 2007 Brian Lawler	Foolish Fantasy Football: Gilead Sciences on Offense For his fantasy football investment team, this stock analyst thinks Gilead packs enough offensive muscle to score in anyone's portfolio.
<Older 4111-4120 Newer> Return to current articles.